Sub menu

 
 

Novartis Pharmaceuticals Australia Pty Limited

Regulatory activities for this sponsor.

Type

Date

29 result(s) found, displaying 1 to 10
  • Australian Public Assessment Report (AusPAR)

    AusPAR: Cosentyx

    AusPAR for Cosentyx (secukinumab) for the treatment of plaque psoriasis, psoriatic arthritis and axial spondyloarthritis etc.
  • Australian Public Assessment Report (AusPAR)

    AusPAR: Inclisiran

    Australian Public Assessment Report for Inclisiran
  • Prescription medicine decision summary

    Leqvio

    Australian prescription medicine decision summary
  • Prescription medicine decision summary

    Zolgensma

    TGA decision: Zolgensma (onasemnogene abeparvovec) is approved to treat patients less than 9 months old with symptomatic/pre-symptomatic SMA.
  • Australian Public Assessment Report (AusPAR)

    AusPAR: Deferasirox

    Australian Public Assessment Report for Deferasirox
  • Australian Public Assessment Report (AusPAR)

    AusPAR: Imatinib

    Australian Public Assessment Report for Imatinib
  • Australian Public Assessment Report (AusPAR)

    AusPAR: Nabiximols

    Australian Public Assessment Report for Nabiximols
  • Australian Public Assessment Report (AusPAR)

    AusPAR: Everolimus

    Australian Public Assessment Report for Everolimus

Help us improve the Therapeutic Goods Administration site